Are there any common side effects of Macitentan (Aoposu) tablets? Full analysis of clinical adverse reactions

Macitentan (Macitentan) is an oral endothelin receptor antagonist (Endothelin Receptor Antagonist, ERA), mainly used to treat pulmonary arterial hypertension (PAH), especially suitable for improving exercise tolerance and delaying disease progression in patients with pulmonary arterial hypertension. It achieves therapeutic effects by antagonizing the activation effect of endothelin-1 (ET-1) on ETA and ETB receptors, reducing pulmonary vascular resistance and improving right heart function. However, as a systemic targeted drug, macitentan is also accompanied by certain adverse reactions during clinical use, which requires a comprehensive analysis.

First of all, from the clinical trial data, the common side effects of macitentan mainly include headache, nasopharyngitis, anemia and edema. The SERAPHIN trial (the Pivotal III randomized controlled trial of macitentan) showed that during long-term follow-up, about 10%-15%of patients experienced mild to moderate headaches, which were usually relieved by symptomatic treatment. The incidence of nasopharyngitis and upper respiratory tract infection is also relatively high, but most of them are mild and patients can continue to take medication. Anemia is a laboratory abnormality worthy of attention during the use of macitentan. The hemoglobin level of some patients decreases, especially those with low basic hemoglobin or other patients with a history of anemia. Regular blood routine monitoring is required.

Secondly, edema is one of the common systemic adverse reactions of macitentan, including peripheral edema and lower limb edema. Most cases are mild to moderate and can be improved by adjusting diuretics and lifestyle. In clinical practice, attention should be paid to distinguishing edema from fluid retention caused by right heart failure or abnormal renal function to avoid delaying treatment. In addition, macitentan may cause liver function abnormalities, including elevated transaminases, and cholestasis may occur in rare patients. It is recommended to regularly monitor liver function before and during treatment, such as AST, ALT, bilirubin and other indicators, in order to detect abnormalities early and adjust the dose.

Thirdly, adverse reactions in the cardiovascular system and respiratory system also require attention. Although macitentan is relatively selective as a ERA, it may still cause symptoms such as a mild drop in blood pressure, heart palpitations, or dizziness. For patients with pulmonary hypertension, cardiac function monitoring is particularly important to prevent deterioration of right ventricular function. At the same time, some patients may experience cough, difficulty breathing or fatigue, which needs to be differentiated from the progression of the disease. It is worth noting that macitentan has certain advantages over early ERA drugs (such as bosentan) in terms of liver toxicity and fluid retention, but the potential risks cannot be ignored.

In addition, there are potential risks when using macitentan in pregnant and breastfeeding women. Animal experiments show that the drug may cause teratogenic effects on the fetus, so it is contraindicated during pregnancy. At the same time, women should take effective contraceptive measures while taking the drug. There is insufficient safety data during lactation, so use is not recommended. In terms of drug interactions, macitentan is mainly metabolized by the liver. Strong CYP3A4 inhibitors (such as ketoconazole) or inducers (such as rifampicin) may affect its blood concentration. Attention should be paid to the risks of combined medication.

Generally speaking, the adverse reactions of macitentan are generally controllable. Common side effects are mostly mild to moderate and can be managed clinically through monitoring, symptomatic treatment and dose adjustment. During use, patients should follow the doctor's guidance, conduct regular blood routine, liver function and cardiac function monitoring, and pay attention to lifestyle adjustments to reduce the risk of adverse reactions. For special groups, such as pregnant women, lactating women and patients with abnormal basic blood or liver function, they should be used with caution after strict risk assessment. Through rational use and scientific monitoring, macitentan can play an important role in improving the prognosis of patients with pulmonary hypertension while ensuring controllable safety.

Reference materials:https://www.drugs.com/